Recall
FDAHealthFebruary 27, 2025

Amgen, Inc. — Neupogen (filgrastim) For Injection, 480 mcg/1.6 mL (300 mcg/1 mL), 1.6 mL single Dose Vial, Rx Only, For Subcutaneous or Intravenous Use Only, Sterile Solution - No Preservative, Amgen

⚠️ Stability data does not support expiry: the products have the potential to be out of specification at the time of expiry of 36-months.

Is this relevant to me?

Geography
Nationwide
Source agency
FDA
Category
Health
Published
February 27, 2025

Nationwide in the U.S.A. and Belgium/Luxembourg, Brazil, Chile, Colombia, France/French Guiana, Germany, Ireland, Italy/San Marino, Netherlands, Poland, Spain/Andorra, Sweden, Finland, Switzerland/Liechtenstein, United Kingdom of Great Britain and Northern Ireland, Ireland, Denmark, Canada, Hong Kong, Philippines, Israel, Malaysia, Saudi Arabia, Gibraltar.

What's affected?

Product
Neupogen (filgrastim) For Injection, 480 mcg/1.6 mL (300 mcg/1 mL), 1.6 mL single Dose Vial, Rx Only, For Subcutaneous or Intravenous Use Only, Sterile Solution - No Preservative, Amgen Inc. Thousand Oaks, CA 91320, NDC 55513-546-01 (vial), NDC 55513-546-10 (box).
UPC
0355513530101
Lot code
1147308

Additional details

Lot 1147308, 1154183, Exp.: 2/28/2025; 1156807, 1160222, Exp.: 6/30/2025; 1160223, 1163912, 1167352, Exp.: 2/28/2026; 1171365, 1175057, 1176250, Exp.: 11/30/2026.

What should I do?

Recommended action

Class II recall. Voluntary: Firm initiated Quantity affected: 258,750 Vials.

View original FDA notice →

Get Health recall alerts

Delivered to your inbox. Free. No account required.